{"filing":{"accession_number":"0001104659-26-102446","cik":"0001649989","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-23","primary_document":"tm2624167d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926102446/tm2624167d1_8k.htm"},"events":[{"id":30031,"run_id":27526,"accession_number":"0001104659-26-102446","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses both the departure of Lawrence A. Kenyon as CFO, Treasurer, and Corporate Secretary effective September 1, 2026, and the appointment of Kevin Lundquist as CFO, Treasurer, principal financial officer and principal accounting officer effective the same date. While both events occur, the principal disclosed action centers on the appointment of Lundquist with detailed compensation arrangements (base salary $450,000, 500,000 stock options, severance terms), making exec_appointment the most salient classification. The departure is secondary context to the transition.","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32515,"accession_number":"0001104659-26-102446","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the departure of Lawrence A. Kenyon as CFO, Treasurer, and Corporate Secretary effective September 1, 2026, and the appointment of Kevin Lundquist as CFO, Treasurer, principal financial officer and principal accounting officer effective the same date. While both events occur, the principal disclosed action centers on the appointment of Lundquist with detailed compensation arrangements (base salary $450,000, 500,000 stock options, severance terms), making exec_appointment the most salient classification. The departure is secondary context to the transition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:13:46.089170+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32515,"accession_number":"0001104659-26-102446","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the departure of Lawrence A. Kenyon as CFO, Treasurer, and Corporate Secretary effective September 1, 2026, and the appointment of Kevin Lundquist as CFO, Treasurer, principal financial officer and principal accounting officer effective the same date. While both events occur, the principal disclosed action centers on the appointment of Lundquist with detailed compensation arrangements (base salary $450,000, 500,000 stock options, severance terms), making exec_appointment the most salient classification. The departure is secondary context to the transition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:13:46.089170+00:00","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-08-27"}]}